GlucoTrack (GCTK) Q2 2026 earnings summary

Executive summary

• Completed a business combination with Lokahi Therapeutics, making Lokahi a wholly owned subsidiary and expanding into biopharmaceuticals for inflammation and pain management alongside diabetes device development.

• Raised capital through multiple financings, including a Bridge Financing, PIPE, and equity line of credit, but faces ongoing liquidity challenges and substantial doubt about ability to continue as a going concern.

• Underwent significant management changes, with Erik Emerson appointed as CEO following the merger.

Financial highlights

• Net loss for Q2 2026 was $3,814, down from $4,756 in Q2 2025; six-month net loss was $8,148, down from $11,589 year-over-year.

• Cash and cash equivalents fell to $1,124 as of June 30, 2026, from $7,383 at year-end 2025.

• Research and development expenses decreased to $2,016 for Q2 2026 from $3,150 in Q2 2025; general and administrative expenses also declined.

• Accumulated deficit reached $159,986 as of June 30, 2026.

Outlook and guidance

• Management expects research and development expenses to increase as clinical trial activities expand, but future spending will depend on available financial resources.

• Current cash is not expected to fund operations for the next twelve months; additional capital raises are anticipated.

• Substantial doubt remains about the ability to continue as a going concern without further financing.